Lilly's orforglipron capsule matches tablet exposure in bioequivalence study
The Phase 1 trial found capsule and tablet forms of the oral GLP-1 pill hit matching blood levels, clearing an operational hurdle as Lilly races rivals to market.
Executive Summary
- A Phase 1 bioequivalence study found Eli Lilly's oral GLP-1 obesity candidate performs the same in blood levels whether given as a capsule or a tablet, clearing a technical bar rather than a clinical efficacy one.
- Because the two formulations behave identically in the body, Lilly can rely on data generated in one form to support the other, smoothing whichever formulation it ultimately commercializes.
- Lilly's oral candidate is racing several other oral and injectable GLP-1 programs toward the obesity market, and formulation flexibility removes one operational variable from that race.
- The finding sits inside a Phase 1 pharmacokinetic program, not the pivotal efficacy trials that will determine the drug's competitive standing.
The finding
Eli Lilly and Company posted results from NCT06440980 showing that orforglipron, its oral small-molecule GLP-1 receptor agonist for obesity, produced equivalent drug exposure whether dosed as a capsule or a tablet. The trial's primary endpoints measured steady-state maximum concentration (Cmax) and area under the concentration-time curve (AUC0-tau) on Day 7 of dosing, comparing the capsule against dose-adjusted tablet strengths across six dose levels. A company disclosure describing the study said the 90% confidence intervals for both measures met the predefined bioequivalence criteria at every dose tested, and that safety profiles were similar between the two forms with no difference in adverse events. NCT06440980+1A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightJul 17, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How it was tested
The trial enrolled 533 healthy adults with obesity or overweight in an open-label, randomized, multi-period crossover design with 14 arms, run at US sites from June 2024 to its primary completion on June 2, 2025. Participants moved through a sequence of dosing periods, receiving orforglipron as tablets and capsules at matched dose levels within the same cohort, with pharmacokinetic sampling out to 24 hours post-dose on Day 7 of each seven-day period. The most frequent adverse events reported across dosing arms were constipation, nausea, and decreased appetite, consistent with the drug's mechanism. NCT06440980A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980
What it changes
Orforglipron already has six completed Phase 1 studies behind it, and this is the largest by enrollment. Because the capsule and tablet forms are now shown to behave the same way in the body, Lilly does not need to re-run its formulation's efficacy and safety case from scratch if it shifts from one presentation to the other. That matters operationally: Lilly is running orforglipron through an extensive Phase 3 program spanning obesity, hypertension, adolescent obesity, osteoarthritis of the knee, and stress urinary incontinence, and a stable capsule-tablet bridge supports manufacturing and regulatory flexibility across that program. NCT06440980A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980
The competitive field
Orforglipron competes with a wide field of GLP-1 receptor agonists in obesity, spanning both injectable peptides and oral small molecules, including Novo Nordisk A/S's semaglutide and other oral small-molecule GLP-1 agonists in Phase 3 obesity testing from AstraZeneca, Hoffmann-La Roche, and Structure Therapeutics. Against that field, a formulation that is stable across capsule and tablet forms is a manufacturing and supply-chain advantage rather than a clinical differentiator; the drug's competitive position will still be decided by its Phase 3 efficacy and safety results, not by this bridging study.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.